Drug Therapy for Rheumatoid Arthritis in Adults
Conclusions (2 of 4)
Indirect comparisons reveal potential differences in effectiveness of the biologic disease-modifying anti-rheumatic drugs (DMARDs) in treating rheumatoid arthritis, but the analysis should be interpreted with caution.
Combining biologic DMARDs provides no additional benefits and increases the risk of serious adverse effects.
In patients with inadequate disease control, biologic DMARDs used in combination with methotrexate (MTX) offer greater relief than monotherapy with either MTX or a biologic DMARD without increasing treatment discontinuation due to adverse effects.
Keywords: rheumatoid arthritis | RA | DMARDs | disease-modifying | antirheumatic | anti-rheumatic | methotrexate | oral DMARD | biologic DMARD | adverse effects
- Donahue KE, Jonas D, Hansen RA, et al. Drug Therapy for Rheumatoid Arthritis in Adults: An Update. Comparative Effectiveness Review No. 55 (Prepared by the RTI International–University of North Carolina Evidence-based Practice Center under Contract No. 290-2007-10056-I). Rockville, MD: Agency for Healthcare Research and Quality; April 2012. AHRQ Publication No. 12-EHC025-EF. Available at www.effectivehealthcare.ahrq.gov/dmardsra.cfm.
Your slide tray is being processed.